EDIT
insider transactionsEditas Medicine, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-16.6K
0 buy · 16.6K sell
Net value · 30d
-$44.8K
$0 in · $44.8K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
3
0 buy · 16.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Amy Parison KEY
SVP, Chief Financial Officer · 10b5-1
$1.3K
464 sh · $2.70
Own -3%
-
Sell·S
CEO · 10b5-1
$41.5K
15.4K sh · $2.70
Own -6%
-
Sell·S
EVP, CHIEF SCIENTIFIC OFFICER · 10b5-1
$2.0K
731 sh · $2.70
Own -1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 3, 2026 | Amy Parison KEY 10b5-1 | Sell S | 464 | $1.3K |
| Jun 3, 2026 | Gilmore Neil O'Neill KEY 10b5-1 | Sell S | 15.4K | $41.5K |
| Jun 3, 2026 | Linda Burkly 10b5-1 | Sell S | 731 | $2.0K |
About EDIT insider trading
This page tracks insider transactions for Editas Medicine, Inc. (EDIT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.